The 127% YoY revenue growth and accelerating patient adds (42,250+) confirm Rezdiffra's blockbuster trajectory. The EPS beat vs consensus is significant, but the widening net loss and $54.3M in one-time BD costs warrant monitoring. Watch for Q2 2026 patient adds and any updates on the oral GLP-1 Phase 1 initiation. The siRNA deal with Arrowhead adds pipeline optionality but near-term focus remains on Rezdiffra's commercial ramp.
Price Chart
Executive Summary
Madrigal Pharmaceuticals reported Q1 2026 Rezdiffra net sales of $311.3M (+127% YoY), beating consensus revenue estimates of $300.9M. The company posted a GAAP net loss of $94.4M (-$3.25/share), which was narrower than the consensus EPS estimate of -$4.14, driven by strong commercial execution and 42,250+ patients on therapy. Management highlighted blockbuster status on a trailing-12-month basis and a rapidly expanding MASH market, but the company remains unprofitable with rising operating expenses.
Key Financial Metrics
Key Facts
- Q1 2026 Rezdiffra net sales of $311.3M, up 127% YoY from $137.3M
- GAAP net loss of $94.4M (-$3.25/share) vs consensus -$4.14 (38% beat)
- 42,250+ patients on Rezdiffra as of March 31, 2026, up 2.5x from Q1 2025
- Cash, equivalents, and marketable securities of $817.9M as of March 31, 2026
- Licensed clinical-stage siRNA asset (ARO-PNPLA3) from Arrowhead Pharmaceuticals on May 5, 2026
- Operating expenses of $404.1M included $54.3M in one-time upfront business development costs
- MGL-2086 (oral GLP-1) Phase 1 trial on track to initiate in Q2 2026
Financial Impact
Revenue beat consensus by ~$10.4M (3.5%); EPS beat by $0.89 (21.5% vs consensus -$4.14). Net loss widened YoY due to $54.3M in upfront BD expenses.
Risk Factors
- Net loss widened to $94.4M from $73.2M YoY, driven by $54.3M in upfront BD expenses
- Operating expenses grew 87% YoY to $404.1M, outpacing revenue growth
- Cash burn: cash decreased $170.7M from Dec 2025 ($988.6M) to March 2026 ($817.9M)
- Dependence on single product (Rezdiffra) for all revenue
- Potential competitive pressure from other MASH therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-030896 |
| Document: mdgl-20260506.htm | 0001628280-26-030896 |
| Document: 0001628280-26-030896-index-headers.html | 0001628280-26-030896 |
| Document: 0001628280-26-030896-index.html | 0001628280-26-030896 |
| Document: 0001628280-26-030896.txt | 0001628280-26-030896 |
| 8-K Data (Synthetic) | 0001628280-26-030896 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | 8-K | $536.20 $533.12 | ▼ −0.57% | ▲ +1.32% | $496.64 (−7.38%) |
Jul 30, 2026 9w ago | 8-K | $493.11 $543.69 | ▲ +10.26% | ▲ +6.29% | $496.64 (+0.71%) |
May 22, 2026 18w ago | Insider Cluster | $524.28 $520.00 | ▼ −0.82% | ▲ +1.13% | $496.64 (−5.27%) |
May 6, 2026 21w ago | 8-K | $539.73 $488.15 | ▼ −9.56% | ▼ −12.34% | $496.64 (−7.98%) |
Apr 28, 2026 22w ago | 8-K | $518.58 $515.96 | ▼ −0.51% | ▼ −6.55% | $496.64 (−4.23%) |
Apr 22, 2026 23w ago | Press Release | $529.14 $511.82 | ▼ −3.27% | ▼ −6.44% | $496.64 (−6.14%) |
Mar 19, 2026 28w ago | Press Release | $441.16 $527.11 | ▲ +19.48% | ▲ +10.16% | $496.64 (+12.57%) |
Mar 2, 2026 30w ago | Insider Cluster | $435.62 $505.34 | ▲ +16.00% | ▲ +23.94% | $496.64 (+14.01%) |
Mar 2, 2026 30w ago | Insider Cluster | $435.62 $505.34 | ▲ +16.00% | ▲ +23.94% | $496.64 (+14.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access